April 29, 2021
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Jason Drory, Office of Life Sciences
Catalyst Biosciences, Inc.
Registration Statement on Form S-3
Filed March 4, 2021
File No. 333-253874
REQUEST FOR ACCELERATION OF EFFECTIVENESS
|Requested Date:||May 3, 2021|
|Requested Time:||4:00 p.m. Eastern Time|
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Catalyst Biosciences, Inc. (the Company) hereby requests that the Securities and Exchange Commission (the Commission) take appropriate action to declare the Companys Registration Statement on Form S-3 (File No. 333-253874) effective at the Requested Date and Requested Time set forth above or as soon thereafter as practicable.
The Company hereby authorizes Stephen Thau, who is an attorney with the Companys outside legal counsel, Orrick, Herrington & Sutcliffe LLP, to orally modify or withdraw this request for acceleration.
The Company requests that it be notified of such effectiveness by a telephone call to Mr. Thau at (212) 506-5076.
[Signature page follows]
|CATALYST BIOSCIENCES, INC.|
/s/ Clinton Musil
|Name: Clinton Musil|
|Title: Chief Financial Officer|
Nassim Usman, Ph.D., Catalyst Biosciences, Inc.
Stephen Thau, Esq., Orrick, Herrington & Sutcliffe LLP